Praxis Precision Medicines, Inc. (PRAX)

54.16 -1.00 (-1.81%) At close: 04:00PM EDT

Praxis Precision Medicines, Inc.

99 High Street
30th Floor
Boston, MA 02110
United States
617 300 8460
https://praxismedicines.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 82

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Marcio Silva De'Souza M.B.A.	President, CEO & Director	1.18M	N/A	1979
Mr. Timothy Edwin Kelly	CFO & Treasurer	691.58k	N/A	1974
Mr. Alex Nemiroff J.D.	General Counsel & Secretary	577.34k	N/A	1980
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.	Co-Founder & Chief Scientific Officer	N/A	N/A	N/A
Lauren Mastrocola	VP of Finance & Principal Accounting Officer	N/A	N/A	N/A
Dr. Karl Hansen Ph.D.	Chief Technical Operations Officer	N/A	N/A	N/A
Alex Kane	VP of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Kelly McCue	Chief People Officer	N/A	N/A	N/A
Ms. Alyssa J. S. Wyant	Chief Regulatory & Quality Officer	N/A	N/A	1975
Ms. Megan T. Sniecinski	Chief Business Officer	N/A	N/A	1982

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Corporate Governance

Praxis Precision Medicines, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.